Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.

Soy intake linked to fewer vasomotor menopausal symptoms in midlife women

14 Nov 2019

Consumption of soy products, but not soy milk, is associated with fewer vasomotor menopausal symptoms (VMS) among middle-aged women, results from a pooled analysis of five studies from the InterLACE* consortium have shown.

In the cross-sectional analysis, no statistically significant evidence of an association existed between soy products (relative risk ratio [RRR], 0.92, 95 percent confidence interval [CI], 0.76–1.11) or soy milk (RRR, 1.24, 95 percent CI, 0.93–1.65) and the odds of reporting frequent or severe VMS.

However, after adjustment for sociodemographic and reproductive factors, an association was found between frequent consumption of soy products (odds ratio [OR], 0.63, 95 percent CI, 0.45–0.89), but not soy milk (OR, 1.11, 95 percent CI, 0.85–1.45), and a lower likelihood of reporting subsequent VMS in prospective analysis.

“These are the first ever findings from pooled observational data of association between consumption of soy products and VMS,” the investigators said.

Data in this study were pooled from 19,351 middle-aged women from five observational studies in Australia, UK, US and Japan that contribute to the InterLACE consortium. Information on soy consumption, VMS and covariates were obtained by self-report.

A total of 11,006 women who had complete data on soy consumption, VMS and covariates at baseline were included in the cross-sectional analysis. The prospective analysis included 4,522 women who were free of VMS at baseline and had complete data on VMS at follow-up. Multinomial logistic regression and binary logistic regression models were used.

Soy products are rich in phyto-oestrogens, plant-based compounds that mimic oestrogen in the body.

*International Collaboration for a Life course Approach to reproductive health and Chronic disease Events

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.